{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:22:12Z","timestamp":1789770132222,"version":"4.0.1"},"reference-count":165,"publisher":"Rockefeller University Press","issue":"11","license":[{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia & Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2T32CA009512-34A1"],"award-info":[{"award-number":["2T32CA009512-34A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50 CA254838-01"],"award-info":[{"award-number":["P50 CA254838-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA251138"],"award-info":[{"award-number":["R01 CA251138"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA283364"],"award-info":[{"award-number":["R01 CA283364"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA242020"],"award-info":[{"award-number":["R01 CA242020"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008884","name":"Edward P. Evans Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL128239"],"award-info":[{"award-number":["R01 HL128239"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rupress.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,4]]},"abstract":"<jats:p>Dysregulation of the flow of information from genomic DNA to RNA to protein occurs within all cancer types. In this review, we described the current state of understanding of how RNA processing is dysregulated in cancer with a focus on mutations in the RNA splicing factor machinery that are highly prevalent in hematologic malignancies. We discuss the downstream effects of these mutations highlighting both individual genes as well as common pathways that they perturb. We highlight examples of how alterations in RNA processing have been harnessed for therapeutic intent as well as to promote the selective toxicity of cancer cells.<\/jats:p>","DOI":"10.1084\/jem.20230891","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T02:20:49Z","timestamp":1724725249000},"update-policy":"https:\/\/doi.org\/10.1084\/jem.crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Aberrant pre-mRNA processing in cancer"],"prefix":"10.1084","volume":"221","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1163-539X","authenticated-orcid":true,"given":"Jeetayu","family":"Biswas","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center 1 Molecular Pharmacology Program, , New York, NY,","place":["USA"]},{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Leukemia Service, Memorial Sloan Kettering Cancer Center 2 Department of Medicine, , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7018-2071","authenticated-orcid":true,"given":"Leora","family":"Boussi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Leukemia Service, Memorial Sloan Kettering Cancer Center 2 Department of Medicine, , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8992-9390","authenticated-orcid":true,"given":"Eytan","family":"Stein","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Leukemia Service, Memorial Sloan Kettering Cancer Center 2 Department of Medicine, , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3907-6171","authenticated-orcid":true,"given":"Omar","family":"Abdel-Wahab","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center 1 Molecular Pharmacology Program, , New York, NY,","place":["USA"]},{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Leukemia Service, Memorial Sloan Kettering Cancer Center 2 Department of Medicine, , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"291","published-online":{"date-parts":[[2024,9,24]]},"reference":[{"key":"2024092416024002000_bib1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000920","article-title":"Ribosome biogenesis is a downstream effector of the oncogenic U2AF1-S34F mutation","volume":"18","author":"Akef","year":"2020","journal-title":"PLoS Biol."},{"key":"2024092416024002000_bib2","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1182\/blood-2023-173496","article-title":"Phase 1\/2 multicenter, open-label study of CTX-712 in patients with relapsed\/refractory acute myeloid leukemia and higher risk myelodysplastic syndromes","volume":"142","author":"Al-Kali","year":"2023","journal-title":"Blood"},{"key":"2024092416024002000_bib3","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1261\/rna.079931.123","article-title":"CPSF3 inhibition blocks pancreatic cancer cell proliferation through disruption of core histone mRNA processing","volume":"30","author":"Alahmari","year":"2024","journal-title":"RNA"},{"key":"2024092416024002000_bib4","doi-asserted-by":"publisher","first-page":"10615","DOI":"10.1038\/ncomms10615","article-title":"Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage","volume":"7","author":"Alsafadi","year":"2016","journal-title":"Nat. Commun."},{"key":"2024092416024002000_bib5","doi-asserted-by":"publisher","first-page":"7070","DOI":"10.1200\/jco.2007.25.18_suppl.7070","article-title":"Phase II dosing study of cytarabine chemotherapy in combination with cenersen (EL625) and idarubicin in refractory and relapsed acute myelogenous leukemia (AML)","volume":"25","author":"Alvarado","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"2024092416024002000_bib6","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41586-019-1832-9","article-title":"KRAS4A directly regulates hexokinase 1","volume":"576","author":"Amendola","year":"2019","journal-title":"Nature"},{"key":"2024092416024002000_bib7","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1182\/blood.2023020400","article-title":"Alternative splicing of its 5\u2032-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies","volume":"142","author":"Ang","year":"2023","journal-title":"Blood"},{"key":"2024092416024002000_bib8","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.chembiol.2018.09.006","article-title":"Decoding transcriptome dynamics of genome-encoded polyadenylation and autoregulation with small-molecule modulators of alternative polyadenylation","volume":"25","author":"Araki","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"2024092416024002000_bib9","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1002\/cncr.31398","article-title":"Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"124","author":"Assi","year":"2018","journal-title":"Cancer"},{"key":"2024092416024002000_bib10","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.3324\/haematol.2014.111245","article-title":"A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E","volume":"100","author":"Assouline","year":"2015","journal-title":"Haematologica"},{"key":"2024092416024002000_bib11","doi-asserted-by":"publisher","first-page":"114048","DOI":"10.1016\/j.celrep.2024.114048","article-title":"Genomic deletions explain the generation of alternative BRAF isoforms conferring resistance to MAPK inhibitors in melanoma","volume":"43","author":"Aya","year":"2024","journal-title":"Cell Rep."},{"key":"2024092416024002000_bib12","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nature24277","article-title":"Genetic effects on gene expression across human tissues","volume":"550","author":"Battle","year":"2017","journal-title":"Nature"},{"key":"2024092416024002000_bib13","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1016\/j.molcel.2024.04.006","article-title":"GPATCH8 modulates mutant SF3B1 mis-splicing and pathogenicity in hematologic malignancies","volume":"84","author":"Benbarche","year":"2024","journal-title":"Mol. Cell"},{"key":"2024092416024002000_bib14","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1080\/10428194.2022.2136952","article-title":"Venetoclax-based salvage therapy in patients with relapsed\/refractory acute myeloid leukemia previously treated with FLT3 or IDH1\/2 inhibitors","volume":"64","author":"Bewersdorf","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"2024092416024002000_bib15","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1038\/s41375-023-02050-4","article-title":"E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: A phase II clinical trial","volume":"37","author":"Bewersdorf","year":"2023","journal-title":"Leukemia"},{"key":"2024092416024002000_bib16","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1101\/gad.219899.113","article-title":"Regulation of constitutive and alternative splicing by PRMT5 reveals a role for Mdm4 pre-mRNA in sensing defects in the spliceosomal machinery","volume":"27","author":"Bezzi","year":"2013","journal-title":"Genes Dev."},{"key":"2024092416024002000_bib17","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature11547","article-title":"Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes","volume":"491","author":"Biankin","year":"2012","journal-title":"Nature"},{"key":"2024092416024002000_bib18","doi-asserted-by":"publisher","first-page":"a039453","DOI":"10.1101\/cshperspect.a039453","article-title":"Imaging organization of RNA processing within the nucleus","volume":"13","author":"Biswas","year":"2021","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2024092416024002000_bib19","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.molcel.2024.02.032","article-title":"Transcription elongation defects link oncogenic SF3B1 mutations to targetable alterations in chromatin landscape","volume":"84","author":"Boddu","year":"2024","journal-title":"Mol. Cell"},{"key":"2024092416024002000_bib20","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.cell.2013.07.033","article-title":"From structure to systems: High-resolution, quantitative genetic analysis of RNA polymerase II","volume":"154","author":"Braberg","year":"2013","journal-title":"Cell"},{"key":"2024092416024002000_bib21","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41568-022-00541-7","article-title":"RNA splicing dysregulation and the hallmarks of cancer","volume":"23","author":"Bradley","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"2024092416024002000_bib22","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abm6360","article-title":"Epigenetically controlled tumor antigens derived from splice junctions between exons and transposable elements","volume":"8","author":"Burbage","year":"2023","journal-title":"Sci. Immunol."},{"key":"2024092416024002000_bib23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"key":"2024092416024002000_bib24","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.chembiol.2021.02.007","article-title":"A synthetic small molecule stalls pre-mRNA splicing by promoting an early-stage U2AF2-RNA complex","volume":"28","author":"Chatrikhi","year":"2021","journal-title":"Cell Chem. Biol."},{"key":"2024092416024002000_bib25","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.1093\/hmg\/ddr370","article-title":"Increased levels of noisy splicing in cancers, but not for oncogene-derived transcripts","volume":"20","author":"Chen","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"2024092416024002000_bib26","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.molcel.2017.12.029","article-title":"The augmented R-loop is a unifying mechanism for myelodysplastic syndromes induced by high-risk splicing factor mutations","volume":"69","author":"Chen","year":"2018","journal-title":"Mol. Cell"},{"key":"2024092416024002000_bib27","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1182\/blood.2019004260","article-title":"Splicing factor mutations in hematologic malignancies","volume":"138","author":"Chen","year":"2021","journal-title":"Blood"},{"key":"2024092416024002000_bib28","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.1038\/s41388-019-0714-9","article-title":"Nudt21 regulates the alternative polyadenylation of Pak1 and is predictive in the prognosis of glioblastoma patients","volume":"38","author":"Chu","year":"2019","journal-title":"Oncogene"},{"key":"2024092416024002000_bib29","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood.2021012652","article-title":"Coordinated missplicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome","volume":"139","author":"Clough","year":"2022","journal-title":"Blood"},{"key":"2024092416024002000_bib30","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/cncr.26292","article-title":"Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia","volume":"118","author":"Cortes","year":"2012","journal-title":"Cancer"},{"key":"2024092416024002000_bib31","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1182\/blood-2011-12-400994","article-title":"Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes","volume":"119","author":"Damm","year":"2012","journal-title":"Blood"},{"key":"2024092416024002000_bib32","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1172\/JCI82534","article-title":"Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth","volume":"126","author":"Dewaele","year":"2016","journal-title":"J. Clin. Invest."},{"key":"2024092416024002000_bib33","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/leu.2014.331","article-title":"Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells","volume":"29","author":"Dolatshad","year":"2015","journal-title":"Leukemia"},{"key":"2024092416024002000_bib34","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1038\/leu.2016.149","article-title":"Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes","volume":"30","author":"Dolatshad","year":"2016","journal-title":"Leukemia"},{"key":"2024092416024002000_bib35","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/j.str.2019.10.005","article-title":"Structural basis and kinetic pathway of RBM39 recruitment to DCAF15 by a sulfonamide molecular glue E7820","volume":"27","author":"Du","year":"2019","journal-title":"Structure"},{"key":"2024092416024002000_bib36","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41586-018-0758-y","article-title":"CDK12 regulates DNA repair genes by suppressing intronic polyadenylation","volume":"564","author":"Dubbury","year":"2018","journal-title":"Nature"},{"key":"2024092416024002000_bib37","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: From immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat. Immunol."},{"key":"2024092416024002000_bib38","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nrc.2016.51","article-title":"RNA splicing factors as oncoproteins and tumour suppressors","volume":"16","author":"Dvinge","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"2024092416024002000_bib39","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41416-023-02276-0","article-title":"Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors","volume":"129","author":"El-Khoueiry","year":"2023","journal-title":"Br. J. Cancer"},{"key":"2024092416024002000_bib40","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nature11143","article-title":"Whole-genome analysis informs breast cancer response to aromatase inhibition","volume":"486","author":"Ellis","year":"2012","journal-title":"Nature"},{"key":"2024092416024002000_bib41","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/0092-8674(88)90202-4","article-title":"Effects of RNA secondary structure on alternative splicing of pre-mRNA: Is folding limited to a region behind the transcribing RNA polymerase?","volume":"54","author":"Eperon","year":"1988","journal-title":"Cell"},{"key":"2024092416024002000_bib42","doi-asserted-by":"publisher","first-page":"6296","DOI":"10.1158\/1078-0432.CCR-13-0485","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors","volume":"19","author":"Eskens","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"2024092416024002000_bib43","doi-asserted-by":"publisher","first-page":"106634","DOI":"10.1016\/j.oraloncology.2023.106634","article-title":"PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study","volume":"149","author":"Ferrarotto","year":"2024","journal-title":"Oral Oncol."},{"key":"2024092416024002000_bib44","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ccell.2019.07.003","article-title":"Therapeutic targeting of RNA splicing catalysis through inhibition of protein arginine methylation","volume":"36","author":"Fong","year":"2019","journal-title":"Cancer Cell"},{"key":"2024092416024002000_bib45","doi-asserted-by":"publisher","first-page":"4084","DOI":"10.1093\/hmg\/ddt258","article-title":"The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models","volume":"22","author":"Gogliotti","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"2024092416024002000_bib46","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/ng.1031","article-title":"Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes","volume":"44","author":"Graubert","year":"2011","journal-title":"Nat. Genet."},{"key":"2024092416024002000_bib47","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.aaz1776","article-title":"The GTEx Consortium atlas of genetic regulatory effects across human tissues","volume":"369","author":"GTEx Consortium","year":"2020","journal-title":"Science"},{"key":"2024092416024002000_bib48","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"key":"2024092416024002000_bib49","doi-asserted-by":"publisher","DOI":"10.1126\/science.aal3755","article-title":"Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15","volume":"356","author":"Han","year":"2017","journal-title":"Science"},{"key":"2024092416024002000_bib50","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1182\/blood-2021-146987","article-title":"Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes","volume":"138","author":"Haque","year":"2021","journal-title":"Blood"},{"key":"2024092416024002000_bib51","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/ng.2523","article-title":"Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma","volume":"45","author":"Harbour","year":"2013","journal-title":"Nat. Genet."},{"key":"2024092416024002000_bib52","doi-asserted-by":"publisher","first-page":"314ra185","DOI":"10.1126\/scitranslmed.aac5272","article-title":"AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer","volume":"7","author":"Hong","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"2024092416024002000_bib53","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.ajhg.2008.01.014","article-title":"Antisense masking of an hnRNP A1\/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice","volume":"82","author":"Hua","year":"2008","journal-title":"Am. J. Hum. Genet."},{"key":"2024092416024002000_bib54","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes Dev."},{"key":"2024092416024002000_bib55","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s41576-023-00684-9","article-title":"Real-time single-molecule imaging of transcriptional regulatory networks in living cells","volume":"25","author":"Hwang","year":"2024","journal-title":"Nat. Rev. Genet."},{"key":"2024092416024002000_bib56","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1101\/gr.181016.114","article-title":"U2AF1 mutations alter splice site recognition in hematological malignancies","volume":"25","author":"Ilagan","year":"2015","journal-title":"Genome Res."},{"key":"2024092416024002000_bib57","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.cell.2012.08.029","article-title":"Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing","volume":"150","author":"Imielinski","year":"2012","journal-title":"Cell"},{"key":"2024092416024002000_bib58","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41586-019-1646-9","article-title":"Spliceosomal disruption of the non-canonical BAF complex in cancer","volume":"574","author":"Inoue","year":"2019","journal-title":"Nature"},{"key":"2024092416024002000_bib59","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41588-021-00828-9","article-title":"Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition","volume":"53","author":"Inoue","year":"2021","journal-title":"Nat. Genet."},{"key":"2024092416024002000_bib60","doi-asserted-by":"publisher","first-page":"5621","DOI":"10.1038\/s41467-020-19514-1","article-title":"Identification of phenothiazine derivatives as UHM-binding inhibitors of early spliceosome assembly","volume":"11","author":"Jagtap","year":"2020","journal-title":"Nat. Commun."},{"key":"2024092416024002000_bib61","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1038\/ng.3414","article-title":"Intron retention is a widespread mechanism of tumor-suppressor inactivation","volume":"47","author":"Jung","year":"2015","journal-title":"Nat. Genet."},{"key":"2024092416024002000_bib62","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ccell.2018.07.001","article-title":"Comprehensive analysis of alternative splicing across tumors from 8,705 patients","volume":"34","author":"Kahles","year":"2018","journal-title":"Cancer Cell"},{"key":"2024092416024002000_bib63","doi-asserted-by":"publisher","first-page":"18105","DOI":"10.1073\/pnas.0406927102","article-title":"Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap","volume":"101","author":"Kentsis","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2024092416024002000_bib64","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"2024092416024002000_bib65","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ccell.2015.04.006","article-title":"SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition","volume":"27","author":"Kim","year":"2015","journal-title":"Cancer Cell"},{"key":"2024092416024002000_bib66","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/febs.16199","article-title":"Identification of a small molecule splicing inhibitor targeting UHM domains","volume":"289","author":"Kobayashi","year":"2022","journal-title":"FEBS J."},{"key":"2024092416024002000_bib67","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41586-022-04451-4","article-title":"Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers","volume":"603","author":"Kobayashi","year":"2022","journal-title":"Nature"},{"key":"2024092416024002000_bib68","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1042\/BST20221347","article-title":"Differential functions of the KRAS splice variants","volume":"51","author":"Kochen Rossi","year":"2023","journal-title":"Biochem. Soc. Trans."},{"key":"2024092416024002000_bib69","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nchembio.2007.16","article-title":"Splicing factor SF3b as a target of the antitumor natural product pladienolide","volume":"3","author":"Kotake","year":"2007","journal-title":"Nat. Chem. Biol."},{"key":"2024092416024002000_bib70","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1038\/s41467-019-09703-y","article-title":"CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation","volume":"10","author":"Krajewska","year":"2019","journal-title":"Nat. Commun."},{"key":"2024092416024002000_bib71","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/978-0-387-77374-2_12","article-title":"The coupling of alternative splicing and nonsense-mediated mRNA decay","volume":"623","author":"Lareau","year":"2007","journal-title":"Adv. Exp. Med. Biol."},{"key":"2024092416024002000_bib72","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/345544a0","article-title":"Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5\u2032 cap","volume":"345","author":"Lazaris-Karatzas","year":"1990","journal-title":"Nature"},{"key":"2024092416024002000_bib73","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/nm.4097","article-title":"Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins","volume":"22","author":"Lee","year":"2016","journal-title":"Nat. Med."},{"key":"2024092416024002000_bib74","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"key":"2024092416024002000_bib75","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1073\/pnas.0136770100","article-title":"Evidence for the widespread coupling of alternative splicing and nonsense-mediated mRNA decay in humans","volume":"100","author":"Lewis","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2024092416024002000_bib76","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2111703119","article-title":"SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes","volume":"119","author":"Lieu","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2024092416024002000_bib77","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1158\/2159-8290.CD-19-1330","article-title":"Mutations in the RNA splicing factor SF3B1 promote tumorigenesis through MYC stabilization","volume":"10","author":"Liu","year":"2020","journal-title":"Cancer Discov."},{"key":"2024092416024002000_bib78","doi-asserted-by":"publisher","DOI":"10.1172\/JCI138315","article-title":"Mutant SF3B1 promotes AKT- and NF-\u03baB-driven mammary tumorigenesis","volume":"131","author":"Liu","year":"2021","journal-title":"J. Clin. Invest."},{"key":"2024092416024002000_bib79","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1038\/s41594-023-01161-x","article-title":"The anticancer compound JTE-607 reveals hidden sequence specificity of the mRNA 3\u2032 processing machinery","volume":"30","author":"Liu","year":"2023","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2024092416024002000_bib80","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1016\/j.cell.2021.05.038","article-title":"Pharmacologic modulation of RNA splicing enhances anti-tumor immunity","volume":"184","author":"Lu","year":"2021","journal-title":"Cell"},{"key":"2024092416024002000_bib81","doi-asserted-by":"publisher","first-page":"6042","DOI":"10.1038\/ncomms7042","article-title":"Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome","volume":"6","author":"Madan","year":"2015","journal-title":"Nat. Commun."},{"key":"2024092416024002000_bib82","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1182\/blood.2020004850","article-title":"SF3B1-mutant MDS as a distinct disease subtype: A proposal from the international working group for the prognosis of MDS","volume":"136","author":"Malcovati","year":"2020","journal-title":"Blood"},{"key":"2024092416024002000_bib83","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/ng.2674","article-title":"Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3","volume":"45","author":"Martin","year":"2013","journal-title":"Nat. Genet."},{"key":"2024092416024002000_bib84","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nrm3742","article-title":"A day in the life of the spliceosome","volume":"15","author":"Matera","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2024092416024002000_bib85","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.cell.2009.06.016","article-title":"Widespread shortening of 3'UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells","volume":"138","author":"Mayr","year":"2009","journal-title":"Cell"},{"key":"2024092416024002000_bib86","doi-asserted-by":"publisher","first-page":"P039","DOI":"10.1158\/1535-7163.TARG-21-P039","article-title":"Abstract P039: A phase 1 dose escalation study of protein arginine methyltransferase 5 (PRMT5) inhibitor PRT543 in patients with advanced solid tumors and lymphoma","volume":"20","author":"McKean","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"key":"2024092416024002000_bib87","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abm6359","article-title":"Noncanonical splicing junctions between exons and transposable elements represent a source of immunogenic recurrent neo-antigens in patients with lung cancer","volume":"8","author":"Merlotti","year":"2023","journal-title":"Sci. Immunol."},{"key":"2024092416024002000_bib88","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1158\/1078-0432.CCR-10-0010","article-title":"Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies","volume":"17","author":"Mita","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"2024092416024002000_bib89","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/s41580-022-00507-5","article-title":"Context-specific regulation and function of mRNA alternative polyadenylation","volume":"23","author":"Mitschka","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2024092416024002000_bib90","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases: Elimination, equilibrium and escape","volume":"27","author":"Mittal","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"2024092416024002000_bib91","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1200\/JCO.2023.41.16_suppl.3008","article-title":"A phase 1 study of the protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor PRT811 in patients (pts) with recurrent high-grade glioma or uveal melanoma (UM)","volume":"41","author":"Monga","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"2024092416024002000_bib92","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1146\/annurev-biochem-060614-034242","article-title":"Regulation of alternative splicing through coupling with transcription and chromatin structure","volume":"84","author":"Naftelberg","year":"2015","journal-title":"Annu. Rev. Biochem."},{"key":"2024092416024002000_bib93","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/s41587-022-01224-2","article-title":"Synthetic introns enable splicing factor mutation-dependent targeting of cancer cells","volume":"40","author":"North","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"2024092416024002000_bib94","doi-asserted-by":"publisher","first-page":"1033348","DOI":"10.3389\/fcell.2022.1033348","article-title":"The role of KRAS splice variants in cancer biology","volume":"10","author":"Nuevo-Tapioles","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"2024092416024002000_bib95","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1158\/2159-8290.CD-19-0399","article-title":"Altered RNA processing in cancer pathogenesis and therapy","volume":"9","author":"Obeng","year":"2019","journal-title":"Cancer Discov."},{"key":"2024092416024002000_bib96","doi-asserted-by":"publisher","first-page":"14562","DOI":"10.1038\/s41598-022-18921-2","article-title":"Exploring the mechanistic link between SF3B1 mutation and ring sideroblast formation in myelodysplastic syndrome","volume":"12","author":"Ochi","year":"2022","journal-title":"Sci. Rep."},{"key":"2024092416024002000_bib97","doi-asserted-by":"publisher","first-page":"TPS7561","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS7561","article-title":"A phase II study of BP1001 (liposomal Grb2 antisense oligonucleotide) in patients with hematologic malignancies","volume":"38","author":"Ohanian","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"2024092416024002000_bib98","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat. Med."},{"key":"2024092416024002000_bib99","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1021\/jm9902638","article-title":"Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle","volume":"42","author":"Owa","year":"1999","journal-title":"J. Med. Chem."},{"key":"2024092416024002000_bib100","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.bbagrm.2012.02.024","article-title":"Complexity of RNA polymerase II elongation dynamics","volume":"1819","author":"Palangat","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"2024092416024002000_bib101","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts","volume":"365","author":"Papaemmanuil","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"2024092416024002000_bib102","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"key":"2024092416024002000_bib103","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1038\/nrm1259","article-title":"Splicing double: Insights from the second spliceosome","volume":"4","author":"Patel","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2024092416024002000_bib104","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1182\/blood-2021-150938","article-title":"A phase 1 dose escalation study of protein arginine methyltransferase 5 (PRMT5) inhibitor PRT543 in patients with myeloid malignancies","volume":"138","author":"Patel","year":"2021","journal-title":"Blood"},{"key":"2024092416024002000_bib105","doi-asserted-by":"publisher","first-page":"100776","DOI":"10.1016\/j.jbior.2020.100776","article-title":"SF3B1 mutant myelodysplastic syndrome: Recent advances","volume":"79","author":"Pellagatti","year":"2021","journal-title":"Adv. Biol. Regul."},{"key":"2024092416024002000_bib106","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nature10662","article-title":"RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)","volume":"480","author":"Poulikakos","year":"2011","journal-title":"Nature"},{"key":"2024092416024002000_bib107","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1182\/blood-2023-182676","article-title":"REM-422, a potent, selective, oral small molecule mRNA degrader of the MYB oncogene, demonstrates anti-tumor activity in mouse xenograft models of AML","volume":"142","author":"Prajapati","year":"2023","journal-title":"Blood"},{"key":"2024092416024002000_bib108","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.cell.2019.12.011","article-title":"SnapShot: Splicing alterations in cancer","volume":"180","author":"Rahman","year":"2020","journal-title":"Cell"},{"key":"2024092416024002000_bib109","doi-asserted-by":"publisher","first-page":"7511","DOI":"10.1093\/nar\/gkw551","article-title":"mRNA capping: Biological functions and applications","volume":"44","author":"Ramanathan","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"2024092416024002000_bib110","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s40425-018-0436-5","article-title":"STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial","volume":"6","author":"Reilley","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"2024092416024002000_bib111","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature03205","article-title":"Regulation of cap-dependent translation by eIF4E inhibitory proteins","volume":"433","author":"Richter","year":"2005","journal-title":"Nature"},{"key":"2024092416024002000_bib112","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1083\/jcb.201207087","article-title":"Antisense-based therapy for the treatment of spinal muscular atrophy","volume":"199","author":"Rigo","year":"2012","journal-title":"J. Cell Biol."},{"key":"2024092416024002000_bib113","doi-asserted-by":"publisher","first-page":"5568","DOI":"10.1093\/nar\/26.24.5568","article-title":"Co-transcriptional commitment to alternative splice site selection","volume":"26","author":"Roberts","year":"1998","journal-title":"Nucleic Acids Res."},{"key":"2024092416024002000_bib114","doi-asserted-by":"publisher","first-page":"102961","DOI":"10.1016\/j.esmoop.2024.102961","article-title":"A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations","volume":"9","author":"Rodon","year":"2024","journal-title":"ESMO Open"},{"key":"2024092416024002000_bib115","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1073\/pnas.77.4.1877","article-title":"A mechanism for RNA splicing","volume":"77","author":"Rogers","year":"1980","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2024092416024002000_bib116","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1158\/1078-0432.CCR-22-2483","article-title":"Phase I study of acalabrutinib plus danvatirsen (AZD9150) in relapsed\/refractory diffuse large B-cell lymphoma including circulating tumor DNA biomarker assessment","volume":"29","author":"Roschewski","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"2024092416024002000_bib117","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41589-019-0424-1","article-title":"CPSF3-dependent pre-mRNA processing as a druggable node in AML and Ewing\u2019s sarcoma","volume":"16","author":"Ross","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"2024092416024002000_bib118","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1016\/j.jmb.2016.04.017","article-title":"Coupling of RNA polymerase II transcription elongation with pre-mRNA splicing","volume":"428","author":"Saldi","year":"2016","journal-title":"J. Mol. Biol."},{"key":"2024092416024002000_bib119","doi-asserted-by":"publisher","first-page":"7103","DOI":"10.1038\/ncomms8103","article-title":"Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing","volume":"6","author":"Salton","year":"2015","journal-title":"Nat. Commun."},{"key":"2024092416024002000_bib120","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1126\/science.1155390","article-title":"Proliferating cells express mRNAs with shortened 3\u2032 untranslated regions and fewer microRNA target sites","volume":"320","author":"Sandberg","year":"2008","journal-title":"Science"},{"key":"2024092416024002000_bib121","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.1038\/ncomms5177","article-title":"Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation","volume":"5","author":"Sashida","year":"2014","journal-title":"Nat. Commun."},{"key":"2024092416024002000_bib122","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1084\/jem.20151121","article-title":"The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition","volume":"213","author":"Sashida","year":"2016","journal-title":"J. Exp. Med."},{"key":"2024092416024002000_bib123","doi-asserted-by":"publisher","first-page":"S742","DOI":"10.1016\/j.annonc.2022.07.580","article-title":"451O Preliminary evidence of clinical activity from phase I and Ib trials of the CLK\/DYRK inhibitor cirtuvivint (CIRT) in subjects with advanced solid tumors","volume":"33","author":"Scott","year":"2022","journal-title":"Ann. Oncol."},{"key":"2024092416024002000_bib124","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.celrep.2018.01.088","article-title":"Somatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types","volume":"23","author":"Seiler","year":"2018","journal-title":"Cell Rep."},{"key":"2024092416024002000_bib125","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/nm.4493","article-title":"H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers","volume":"24","author":"Seiler","year":"2018","journal-title":"Nat. Med."},{"key":"2024092416024002000_bib126","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/0076-6879(90)83018-5","article-title":"Splice junctions, branch point sites, and exons: Sequence statistics, identification, and applications to genome project","volume":"183","author":"Senapathy","year":"1990","journal-title":"Methods Enzymol."},{"key":"2024092416024002000_bib127","doi-asserted-by":"publisher","first-page":"7155","DOI":"10.1093\/nar\/15.17.7155","article-title":"RNA splice junctions of different classes of eukaryotes: Sequence statistics and functional implications in gene expression","volume":"15","author":"Shapiro","year":"1987","journal-title":"Nucleic Acids Res."},{"key":"2024092416024002000_bib128","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adj0123","article-title":"Therapeutic targeting of CPSF3-dependent transcriptional termination in ovarian cancer","volume":"9","author":"Shen","year":"2023","journal-title":"Sci. Adv."},{"key":"2024092416024002000_bib129","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1200\/JCO.2022.40.16_suppl.3080","article-title":"A first-in-human phase I study of CTX-712 in patients with advanced, relapsed or refractory malignant tumors","volume":"40","author":"Shimizu","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"2024092416024002000_bib130","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/nbt.4239","article-title":"Intron retention is a source of neoepitopes in cancer","volume":"36","author":"Smart","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"2024092416024002000_bib131","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41556-019-0314-5","article-title":"U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies","volume":"21","author":"Smith","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"2024092416024002000_bib132","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov."},{"key":"2024092416024002000_bib133","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/s43018-022-00384-z","article-title":"Dysregulation and therapeutic targeting of RNA splicing in cancer","volume":"3","author":"Stanley","year":"2022","journal-title":"Nat. Cancer"},{"key":"2024092416024002000_bib134","doi-asserted-by":"publisher","first-page":"3542","DOI":"10.1038\/s41375-021-01328-9","article-title":"Phase I first-in-human dose escalation study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms","volume":"35","author":"Steensma","year":"2021","journal-title":"Leukemia"},{"key":"2024092416024002000_bib135","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.canlet.2017.09.026","article-title":"NUDT21 regulates 3\u2032-UTR length and microRNA-mediated gene silencing in hepatocellular carcinoma","volume":"410","author":"Sun","year":"2017","journal-title":"Cancer Lett."},{"key":"2024092416024002000_bib136","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.cell.2014.01.051","article-title":"Synonymous mutations frequently act as driver mutations in human cancers","volume":"156","author":"Supek","year":"2014","journal-title":"Cell"},{"key":"2024092416024002000_bib137","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1517\/13543784.12.2.283","article-title":"Indisulam: An anticancer sulfonamide in clinical development","volume":"12","author":"Supuran","year":"2003","journal-title":"Expert Opin. Investig. Drugs"},{"key":"2024092416024002000_bib138","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1093\/emboj\/20.7.1785","article-title":"SC35 autoregulates its expression by promoting splicing events that destabilize its mRNAs","volume":"20","author":"Sureau","year":"2001","journal-title":"EMBO J."},{"key":"2024092416024002000_bib139","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1021\/acschembio.2c00145","article-title":"Targeted degradation of mRNA decapping enzyme DcpS by a VHL-recruiting PROTAC","volume":"17","author":"Swartzel","year":"2022","journal-title":"ACS Chem. Biol."},{"key":"2024092416024002000_bib140","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.chembiol.2023.10.019","article-title":"Anticancer benzoxaboroles block pre-mRNA processing by directly inhibiting CPSF3","volume":"31","author":"Tao","year":"2024","journal-title":"Cell Chem. Biol."},{"key":"2024092416024002000_bib141","doi-asserted-by":"publisher","first-page":"CT112","DOI":"10.1158\/1538-7445.AM2021-CT112","article-title":"Abstract CT112: Initial results from a Phase 1 trial of a first-in-class pan-CDC-like kinase inhibitor (SM08502) with proof of mechanism in subjects with advanced solid tumors","volume":"81","author":"Tolcher","year":"2021","journal-title":"Cancer Res."},{"key":"2024092416024002000_bib142","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/wrna.1141","article-title":"The significant other: Splicing by the minor spliceosome","volume":"4","author":"Turunen","year":"2013","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"2024092416024002000_bib143","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/nchembio.2363","article-title":"Selective degradation of splicing factor CAPER\u03b1 by anticancer sulfonamides","volume":"13","author":"Uehara","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"2024092416024002000_bib144","doi-asserted-by":"publisher","first-page":"S25.003","DOI":"10.1212\/WNL.78.1_supplement.S25.003","article-title":"The Therapeutic Effects of RG3039 in Severe Spinal Muscular Atrophy Mice and Normal Human Volunteers (S25.003)","volume":"78","author":"Van Meerbeke","year":"2012","journal-title":"Neurology"},{"key":"2024092416024002000_bib145","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1146\/annurev-genet-120215-034854","article-title":"Single-cell and single-molecule analysis of gene expression regulation","volume":"50","author":"Vera","year":"2016","journal-title":"Annu. Rev. Genet."},{"key":"2024092416024002000_bib146","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1182\/bloodadvances.2021004233","article-title":"Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (alliance)","volume":"5","author":"Walker","year":"2021","journal-title":"Blood Adv."},{"key":"2024092416024002000_bib147","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1109016","article-title":"SF3B1 and other novel cancer genes in chronic lymphocytic leukemia","volume":"365","author":"Wang","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"2024092416024002000_bib148","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccell.2019.01.010","article-title":"Targeting an RNA-binding protein network in acute myeloid leukemia","volume":"35","author":"Wang","year":"2019","journal-title":"Cancer Cell"},{"key":"2024092416024002000_bib149","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ccell.2022.12.002","article-title":"Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia","volume":"41","author":"Wang","year":"2023","journal-title":"Cancer Cell"},{"key":"2024092416024002000_bib150","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1182\/blood-2019-130337","article-title":"A phase I\/II study to investigate the safety and clinical activity of the protein arginine methyltransferase 5 inhibitor GSK3326595 in subjects with myelodysplastic syndrome and acute myeloid leukemia","volume":"134","author":"Watts","year":"2019","journal-title":"Blood"},{"key":"2024092416024002000_bib151","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1182\/blood.2019004261","article-title":"Gene expression at a single-molecule level: Implications for myelodysplastic syndromes and acute myeloid leukemia","volume":"138","author":"Wheat","year":"2021","journal-title":"Blood"},{"key":"2024092416024002000_bib152","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1158\/2159-8290.CD-21-0508","article-title":"Integrative RNA-omics discovers GNAS alternative splicing as a phenotypic driver of splicing factor-mutant neoplasms","volume":"12","author":"Wheeler","year":"2022","journal-title":"Cancer Discov."},{"key":"2024092416024002000_bib153","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1146\/annurev-biochem-091719-064225","article-title":"RNA splicing by the spliceosome","volume":"89","author":"Wilkinson","year":"2020","journal-title":"Annu. Rev. Biochem."},{"key":"2024092416024002000_bib154","doi-asserted-by":"publisher","first-page":"a003707","DOI":"10.1101\/cshperspect.a003707","article-title":"Spliceosome structure and function","volume":"3","author":"Will","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2024092416024002000_bib155","doi-asserted-by":"publisher","first-page":"5274","DOI":"10.1038\/ncomms6274","article-title":"Dynamic analyses of alternative polyadenylation from RNA-seq reveal a 3\u2032-UTR landscape across seven tumour types","volume":"5","author":"Xia","year":"2014","journal-title":"Nat. Commun."},{"key":"2024092416024002000_bib156","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1038\/s41388-021-01693-w","article-title":"Downregulation of NUDT21 contributes to cervical cancer progression through alternative polyadenylation","volume":"40","author":"Xing","year":"2021","journal-title":"Oncogene"},{"key":"2024092416024002000_bib157","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.ccell.2018.01.012","article-title":"Genome-wide CRISPR-cas9 screen identifies leukemia-specific dependence on a pre-mRNA metabolic pathway regulated by DCPS","volume":"33","author":"Yamauchi","year":"2018","journal-title":"Cancer Cell"},{"key":"2024092416024002000_bib158","doi-asserted-by":"publisher","first-page":"6211","DOI":"10.1182\/blood-2022-157241","article-title":"A first-in-human phase I study of CTX-712 in patients with advanced, relapsed or refractory malignant tumors - hematologic malignancies dose escalation cohort","volume":"140","author":"Yokoyama","year":"2022","journal-title":"Blood"},{"key":"2024092416024002000_bib159","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"key":"2024092416024002000_bib160","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ccell.2018.02.015","article-title":"Targeting mRNA decapping in AML","volume":"33","author":"Yoshimi","year":"2018","journal-title":"Cancer Cell"},{"key":"2024092416024002000_bib161","doi-asserted-by":"publisher","first-page":"E4726","DOI":"10.1073\/pnas.1514105112","article-title":"Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities","volume":"112","author":"Zhang","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2024092416024002000_bib162","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.molcel.2019.07.017","article-title":"Disease-causing mutations in SF3B1 alter splicing by disrupting interaction with SUGP1","volume":"76","author":"Zhang","year":"2019","journal-title":"Mol. Cell"},{"key":"2024092416024002000_bib163","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1101\/gad.351154.123","article-title":"Characterization of the SF3B1-SUGP1 interface reveals how numerous cancer mutations cause mRNA missplicing","volume":"37","author":"Zhang","year":"2023","journal-title":"Genes Dev."},{"key":"2024092416024002000_bib164","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1158\/2643-3230.BCD-21-0087","article-title":"Modulation of CD22 protein expression in childhood leukemia by pervasive splicing aberrations: Implications for CD22-directed immunotherapies","volume":"3","author":"Zheng","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"2024092416024002000_bib165","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40364-020-00220-5","article-title":"The biological function and clinical significance of SF3B1 mutations in cancer","volume":"8","author":"Zhou","year":"2020","journal-title":"Biomark. Res."}],"container-title":["Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/doi\/10.1084\/jem.20230891\/1932746\/jem_20230891.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/doi\/10.1084\/jem.20230891\/1932746\/jem_20230891.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T12:03:10Z","timestamp":1727179390000},"score":1,"resource":{"primary":{"URL":"https:\/\/rupress.org\/jem\/article\/221\/11\/e20230891\/276986\/Aberrant-pre-mRNA-processing-in-cancerAberrant-pre"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,24]]},"references-count":165,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11,4]]}},"URL":"https:\/\/doi.org\/10.1084\/jem.20230891","relation":{},"ISSN":["0022-1007","1540-9538"],"issn-type":[{"value":"0022-1007","type":"print"},{"value":"1540-9538","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,24]]},"article-number":"e20230891"}}